NYSEARCA:XBI SPDR S&P Biotech ETF (XBI) Price, Holdings, & News $133.79 +1.05 (+0.79%) As of 06/12/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatingsShort InterestBuy This Stock About SPDR S&P Biotech ETF (NYSEARCA:XBI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SPDR S&P Biotech ETF alerts:Sign Up Key Stats Today's Range$132.96▼$135.5450-Day Range$126.79▼$138.6752-Week Range$80.90▼$139.19Volume7.82 million shsAverage Volume9.22 million shsMarket Capitalization$8.54 billionAssets Under Management$8.23 billionDividend Yield0.33%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF Overview SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Read More SPDR S&P Biotech ETF ExpensesTypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.56%0.57%0.51%0.53%Other Expenses0.00%0.47%0.55%0.58%0.55%Total Expense0.35%0.74%0.76%0.74%0.73%Fee Waiver0.00%-0.71%-0.64%-0.70%-0.62%Net Expense0.35%0.59%0.63%0.58%0.60% Receive XBI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XBI ETF News HeadlinesBiotech stocks are losing momentum despite rising M&A activityJune 10, 2026 | msn.com3 Longevity ETFs to Buy and Hold (and Hold)The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space.June 8, 2026 | marketbeat.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.June 14 at 1:00 AM | Porter & Company (Ad)‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-CovidJune 4, 2026 | cnbc.comVHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and CostMay 28, 2026 | finance.yahoo.com2 Ways to Play the Big Pharma Patent CliffWith hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.May 14, 2026 | marketbeat.comSee More Headlines XBI ETF - Frequently Asked Questions How have XBI shares performed this year? SPDR S&P Biotech ETF's stock was trading at $121.93 at the beginning of the year. Since then, XBI stock has increased by 9.7% and is now trading at $133.79. Who are SPDR S&P Biotech ETF's major shareholders? SPDR S&P Biotech ETF's top institutional investors include Bank of America Corp DE (22.76%), Healthcare of Ontario Pension Plan Trust Fund (15.28%), Bessemer Group Inc. (2.83%) and Meitav Investment House Ltd. (1.27%). How do I buy shares of SPDR S&P Biotech ETF? Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of SPDR S&P Biotech ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM). Fund Details IssuerSSgA Fund NameSPDR S&P Biotech ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XBI Inception Date1/31/2006 Fund ManagerMichael Feehily, Karl Schneider, Raymond Donofrio Webwww.spdrs.com Phone+1-866-7872257Fund Focus Asset ClassEquity BenchmarkS&P Biotechnology Select Industry Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings165 Fund Statistics Assets Under Management$8.23 billion Average Daily Volume$8.25 million Discount/Premium0.03% Administrator, Advisor and Custodian AdministratorState Street Global Advisors Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume21,505 Put Options11,978 Call Options9,527 Short Interest76,993,110 shs Miscellaneous Outstanding Shares63,800,000Beta0.85 Creation Unit50,000 Creation Fee$250.00 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report Top 10 XBI HoldingsTwist Bioscience (NASDAQ:TWST)Holding Weight: 1.82%Alkermes (NASDAQ:ALKS)Holding Weight: 1.80%Revolution Medicines (NASDAQ:RVMD)Holding Weight: 1.80%Travere Therapeutics (NASDAQ:TVTX)Holding Weight: 1.80%TG Therapeutics (NASDAQ:TGTX)Holding Weight: 1.67%Arrowhead Pharmaceuticals (NASDAQ:ARWR)Holding Weight: 1.49%Neurocrine Biosciences (NASDAQ:NBIX)Holding Weight: 1.49%Beam Therapeutics (NASDAQ:BEAM)Holding Weight: 1.45%Exelixis (NASDAQ:EXEL)Holding Weight: 1.45%Apogee Therapeutics (NASDAQ:APGE)Holding Weight: 1.40%Full Holdings DetailsXBI Sector ExposureXBI Industry Exposure This page (NYSEARCA:XBI) was last updated on 6/14/2026 by MarketBeat.com Staff. From Our PartnersRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredThe number nobody's bragging aboutSPCX - the largest IPO in history - was predicted to open at $175. It opened at $150. Insiders bought in at a ...Behind the Markets | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredThere’s a new type of capitalismThe U.S. government has taken direct equity positions in at least 10 companies - Intel, U.S. Steel, Westinghou...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Biotech ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Biotech ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
